For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
Set yourself up for success with recombinant antibodies.
Recombinant monoclonal antibody manufacture occurs in vitro by cloning antibody genes into high-yield expression vectors. These vectors are then introduced into expression hosts to generate recombinant antibodies.
In comparison, monoclonal antibodies made using hybridoma technology are produced when B cells from an immunized animal are immortalized by fusion to a myeloma. While this technique produces highly consistent, specific, and sensitive monoclonal antibodies in large quantities, over time hybridoma cell lines can experience genetic drift, resulting in slight variations to the antibodies produced. Antibodies against difficult targets, ie toxins, nucleotides, and membrane-bound proteins, can’t always be made with this in vivo model either.
Recombinantly manufactured antibodies overcome the limitations of other methods of antibody manufacture to give you the highest level of consistency between batches, confirmed specificity, and a guaranteed long-term supply. Watch our video below to find out what these advantages mean for your research.
Because recombinant antibodies are developed from a unique set of genes, recombinant antibody production is controlled and reliable. Several problems with hybridoma production can be avoided, such as gene loss, gene mutations, and cell-line drift. This leads to antibodies with very high batch-to-batch consistency, giving you the highly reproducible results your research or drug development research requires.
With recombinant technology, it is easier to improve antibody sensitivity through antibody engineering. The selection process for the desired clone occurs at both the hybridoma and recombinant cloning stages, allowing us to select the most favorable antibody qualities.
To ensure specificity, we use extensive validation methods, including knockout validation, to give you confidence in your results. The following examples demonstrate the differences in specificity between recombinant antibodies and other antibody types because the expected molecular weight band disappears in the knockout sample:
Figure 2. Our recombinant anti-TLE 1 antibody [EPR9386(2)] (left) being tested on knockout and wild-type samples against a monoclonal anti-TLE 1 [OTI1F5] antibody.
Figure 3. Our recombinant anti-GRIM19 [EPR4471(2)] antibody (left) being tested on knockout and wild-type samples against our monoclonal anti-GRIM19 [6E1BH7]
KD value is a quantitative measure of antibody affinity. The lower the KD value, the higher the affinity of the antibody. On average, our recombinant RabMab antibodies have KD values in the picomolar (10-10–10-12) range, which is considered to be very high affinity.
High-affinity antibodies allow greater sensitivity in assays, as they bind strongly to the antigen and maintain this bond better under difficult conditions compared to low-affinity antibodies. Analysis of KD values of our recombinant anti-PDL1 antibody shows that its affinity remains high across 5 different batches (Table 1).
With the antibody genes isolated and the sequence known, antibody expression can be carried out at any scale and the long-term supply of antibody is guaranteed. This makes recombinant antibodies a great solution for long-term studies or using the same antibody across multiple samples.
Once the antibody-producing genes are isolated, high-throughput in vitro manufacture can be implemented. For antibodies generated using our phage display technology, even the gene of the antibody can be isolated with an animal-free procedure.